AbbVie Adjusts 2026 Guidance
AbbVie raised its full-year adjusted diluted earnings per share band by $0.05-$0.09, largely due to a $216 million non-GAAP acquired IPR&D and milestones expense, though this is expected to drop off in 2027.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed